Loading
Nerve Injury and Regeneration · Journal article
Advanced Healthcare Materials · August 6, 2026
Encouraging direction, but not yet definitive.
This preclinical proof-of-concept study describes a combinatorial platform of CRISPR-engineered MSCs encapsulated in a self-healing hydrogel, tested in a murine TBI model. The treatment produced multiple favourable endpoints including reduced lesion volume and edema, suppression of microglial inflammation, and improvements in sensorimotor function and spatial memory. The work addresses a genuine bottleneck in cell therapy—retention and survival—but remains at the preclinical stage without human data or formal comparative efficacy trials.
Preclinical in vivo study using a murine traumatic brain injury model. Mice with experimentally induced traumatic brain injury; no strain, age, or other demographic details stated. Intervention: Injectable supramolecular gelatin hydrogel (iGel) encapsulating CRISPR-SAM-engineered mesenchymal stem cells (SPMSCs) programmed to express IL-10 and FGF21.
iGel-encapsulated SPMSCs enhanced SPMSC viability and sustained factor secretion compared to 2D cultures Treatment suppressed microglial inflammation and neuronal apoptosis while restoring blood-brain barrier integrity in murine TBI Treated mice exhibited reduced cerebral edema and lesion volume with significant improvements in sensorimotor function and spatial memory
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
A single-centre preclinical study in a murine TBI model demonstrating efficacy of an engineered cell-biomaterial platform on multiple endpoints including lesion volume, edema, and functional recovery, but lacking human translation, replication, or direct comparator arm.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Traumatic brain injury (TBI) triggers complex secondary pathologies that lack effective treatments. While mesenchymal stem cell (MSC) transplantation is promising, it is severely limited by poor cell retention and survival. To address these challenges, we engineered a combinatorial platform comprising an injectable, self-healing supramolecular gelatin hydrogel (iGel) loaded with CRISPR-SAM-engineered "Super MSCs" (SPMSCs). These cells were programmed to endogenously multiplex the activation of neuroprotective factors IL-10 and FGF21. Our results demonstrate that the biomimetic iGel niche enhances SPMSC viability and sustained factor secretion compared to 2D cultures. In a murine TBI model, iGel-encapsulated SPMSCs exerted potent immunomodulatory effects, suppressing microglial inflammation and neuronal apoptosis while restoring blood-brain barrier integrity. Furthermore, the treatment promoted angiogenesis and endogenous neurogenesis. Consequently, treated mice exhibited reduced cerebral edema and lesion volume, alongside significant improvements in sensorimotor function and spatial memory. This study establishes a versatile, gene-editing-empowered biomaterial platform that overcomes critical bottlenecks in cell therapy for central nervous system injuries.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.